Health Care

Drug prices are driven by patent monopolies, making reform not just PBM regulation key to affordability.

Lower drug prices come from reforming patents and funding research, not tariffs or political dealmaking.

The rapid price decline of Ozempic in global generic markets shows that patent protections not manufacturing costs are the main reason prescription drugs remain expensive in the United States.

Despite strong wage growth, rising out-of-pocket health care costs are fueling affordability concerns, highlighting the need for reforms to lower drug prices, doctor pay, and insurance bureaucracy.

Publicly funded drug research—like the system proposed in Rep. Rashida Tlaib’s bill—could replace patent monopolies, reducing prices and corruption while still supporting innovation.

The Trump administration’s idea of dealing with health care affordability: Promoting shoddy insurance coverage that shifts costs to patients.

Trump’s proposed hospital ship for Greenland is a performative gesture that overlooks Greenland’s universal health care and the far more serious access and life expectancy problems in the United States, including Louisiana.

By failing to capture higher deductibles, copays, and other out-of-pocket medical expenses, the CPI likely overstates real wage growth and helps explain why many households feel worse off despite strong wage data.

While routine dishonesty defines the Trump administration, Robert F. Kennedy, Jr. stands out for spreading baseless vaccine lies that are reviving measles and putting children’s lives at risk under Donald Trump.

Research shows that workers experiencing income volatility are more likely to have interruptions in their access to health care.